Research Article| Volume 21, ISSUE 9, P1549-1562, September 1999

The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: A comparison of Hylan G-F 20 and a lower-molecular-weight hyaluronan

      This paper is only available as a PDF. To read, Please Download here.


      The objective of this 12-week, doublemasked, randomized, multicenter study was to compare the elastoviscous properties of a high-molecular-weight viscosupplement, hylan G-F 20 (polymer concentration, 0.8%), with those of a lower-molecularweight hyaluronan (LMW HA) product (polymer concentration, 1%) and to determine the relationship of elastoviscosity to efficacy in the treatment of patients with osteoarthritis (OA) of the knee. Patients had radiographically confirmed primary idiopathic OA of the knee (Larsen grades I to V) with pain despite other treatments. After a 2-week washout period, 70 patients (73 knees) received three 2-mL intra-articular injections of test solution at 1-week intervals. Thirty-eight patients (38 knees) received hylan G-F 20, and 32 patients (35 knees) received LMW HA. During the 12-week follow-up period, the primary outcome measures assessed by patients (using a visual analogue scale) were weight-bearing pain, most painful knee movement, and overall treatment response; the primary outcome measures assessed by study evaluators were weight-bearing pain and overall assessment of treatment. The dynamic elastoviscous properties of the test solutions were measured on an oscillating Couettetype rheometer. Hylan G-F 20 was more elastoviscous than the LMW HA at all frequencies measured (0.001 to 10 Hz). At the final evaluation, patients who received hylan G-F 20 had significantly better results on all primary outcome measures compared with those who received LMW HA. No systemic adverse events were reported. Local adverse events consisted of pain or swelling, noted in 2 of 38 knees injected with hylan G-F 20, and pain, noted in 1 of 35 knees injected with LMW HA (adverse event rates per injection, 1.8% and 0.9%, respectively). The difference in the incidence of adverse events between groups was not statistically significant. The higher-molecular-weight, more elastoviscous hylan G-F 20 had significantly greater pain-relieving effects than did the lower-molecular-weight, less elastoviscous hyaluronan.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rydell NW
        • Butler J
        • Balazs EA
        Hyaluronic acid in synovial fluid. VI. Effect of intraarticular injection of hyaluronic acid in the clinical symptoms of arthritis in track horses.
        Acta Vet Scand. 1970; 11: 139-155
        • Balazs EA
        • Denlinger JL
        Sodium hyaluronate and joint function.
        J Equine Vet Sci. 1985; 5: 217-228
        • Peyron JG
        • Balazs EA
        Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joints.
        Pathol Biol. 1974; 22: 731-736
        • Weiss C
        • Balazs EA
        • St. Onge R
        • Denlinger JL
        Clinical studies of the intra-articular injection of Healon® (sodium hyaluronate) in the treatment of osteoarthritis of human knees.
        in: Semin Arthritis Rheum. 11. 1981: 143-144
      1. Balazs EA(inventor), Biotrics, Inc., assignee. Ultrapure hyaluronic acid and the use thereof, US patent 4 141 973 February 27 1979.

        • Lohmander LS
        A controlled, randomized, double-blind multicenter trial of intraarticular hyaluronan treatment in osteoarthrosis of the knee.
        Acta Orthop Scand. 1995; 66: 35-36
        • Dahlberg L
        • Lohmander LS
        • Ryd L
        Intraarticular injections of hyaluronan in patients with cartilage abnormalities, knee pain. A one-year double-blind, placebocontrolled study.
        Arthritis Rheum. 1994; 37: 521-528
        • Henderson E
        • Smith E
        • Pegley F
        • Blake D
        Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: A randomised single centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy.
        Ann Rheum Dis. 1994; 53: 529-534
        • Altman RD
        • Moskowitz R
        • For the Hyalgan Study Group
        Intraarticular sodium hyaluronate (Hyalgan®) in the treatment of patients with osteoarthritis of the knee: A randomized clinical trial.
        J Rheumatol. 1998; 25: 2203-2212
        • Balazs EA
        • Denlinger JL
        Viscosupplementation: A new concept in the treatment of osteoarthritis.
        J Rheumatol. 1993; 20: 3-9
      2. (inventors)
        • Balazs EA
        • Leshchiner A
        • Leshchiner A
        • Band P
        Biomatrix, Inc., assignee. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues.
        (US patent 4 713 448 December 15)1985
      3. (inventors)
        • Balazs EA
        • Leshchiner A
        Biomatrix, Inc., assignee. Cross-linked gels of hyaluronic acid and products containing such gels.
        (US patent 4 636 524 January 13)1987
        • Balazs EA
        • Leshchiner A
        Hyaluronan, its crosslinked derivative —hylan — and their medical applications.
        in: Inagaki H Phillips GO Cellulosics Utilization: Research and Rewards in Cellulosics (Proceedings of Nisshinbo International Conference on Cellulosics Utilization in the Near Future). Elsevier Applied Science, New York1989: 233-241
        • Balazs EA
        The physical properties of synovial fluid and the special role of hyaluronic acid.
        in: Helfet AJ Disorders of the Knee. 2nd ed. J.B. Lippincott, Philadelphia1982: 61-74
        • Scale D
        • Wobig M
        • Wolpert W
        Viscosupplementation of osteoarthritic knees with hylan: A treatment schedule study.
        Curr Ther Res. 1994; 55: 220-232
        • Wobig M
        • Dickhut A
        • Maier R
        • Vetter G
        Viscosupplementation with hylan G-F 20: A 26-week controlled trial of efficacy and safety in the osteoarthritic knee.
        Clin Ther. 1998; 20: 410-423
      4. (November 7–11)
        • Moreland L
        • Arnold W
        • Saway A
        • et al.
        Efficacy and safety of intra-articular hylan G-F 20 (Synvisc®), a viscoelastic derivative of hyaluronan, in patients with osteoarthritis of the knee.
        (San Antonio, Texas. Abstract)in: Presented at the annual meeting of the American College of Rheumatology. 1993
        • Adams ME
        • Atkinson MH
        • Lussier AJ
        • et al.
        The role of viscosupplementation with hylan G-F 20 (Synvisc®) in the treatment of osteoarthritis of the knee: A Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone.
        Osteoarthritis Cartilage. 1995; 3: 213-225
        • Balazs EA
        • Watson D
        • Duff IF
        • Roseman S
        Hyaluronic acid in synovial fluid. 1. Molecular parameters of hyaluronic acid in normal and arthritic human fluids.
        Arthritis Rheum. 1967; 10: 357-376
        • Balazs EA
        Viscoelastic properties of hyaluronic acid and biological lubrication (proceedings of symposium: Prognosis for Arthritis: Rheumatology Research Today and Prospects for Tomorrow [1967]).
        Univ Mich Med Ctr J. 1968; 9: 255-259
        • Balazs EA
        • Briller SO
        • Denlinger JE
        Nahyaluronate molecular size variations in equine and human arthritic synovial fluids and the effects on phagocytic cells.
        in: Semin Arthritis Rheum. 11. 1981: 141-143
        • Balazs EA
        • Denlinger JL
        Clinical uses of hyaluronan.
        in: Evered D Whelan J The Biology of Hyaluronan. Ciba Foundation Symposium 143. John Wiley & Sons, New York1989: 265-280
        • Phillips MW
        Clinical trial comparison of intra-articular sodium hyaluronate products in the horse.
        J Equine Vet Sci. 1989; 9: 39-40
        • Rydell N
        • Balazs EA
        Effect of the intraarticular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation.
        Clin Orthop. 1971; 80: 25-32
        • Gotoh S
        • Miyazaki K
        • Onaya J
        • et al.
        Experimental knee pain model in rats and an-algesic effect of sodium hyaluronate (SPH).
        Folia Pharmacol Jpn. 1988; 92: 17-27
        • Gotoh S
        • Onaya J-I
        • Abe M
        • et al.
        Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats.
        Ann Rheum Dis. 1993; 52: 817-822
        • Pozo MA
        • Balazs EA
        • Belmonte C
        Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative.
        Exp Brain Res. 1997; 116: 3-9
      5. Bohlin VOR Software User Manual Version 2.7. Bohlin Reologi AB, Lund, Sweden1989
        • Ferry JD
        Illustrations of viscoelastic behavior of polymeric systems.
        in: Viscoelastic Properties of Polymers. John Wiley & Sons, New York1961: 21-40
        • Larsen A
        • Dale K
        • Eek M
        Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films.
        Acta Radiol Diagn. 1977; 18: 481-491
        • Price DD
        • Harkins SW
        Combined use of experimental pain and visual analogue scales in providing standardized measurement of clinical pain.
        Clin J Pain. 1987; 3: 1-8
        • Bellamy N
        • Appendix A
        Western Ontario and McMaster Universities Osteoarthritis Index (WOMAQ — VA3.0..
        in: Musculoskeletal Clinical Metrology. Kluwer Academic, Dordrecht, Netherlands1993: 320-324
        • Bellamy N
        Outcome measurement in osteoarthritis clinical trials.
        J Rheumatol. 1995; 22: 49-51
        • Milliken GA
        • Johnson DE
        Analysis of Messy Data. Vol 1. Designed Experiments. Van Nostrand-Reinhold, New York1984
        • Bellamy N
        in: Musculoskeletal Clinical Metrology. Kluwer Academic, Dordrecht, Netherlands1993: 169-176
        • Altman R
        Design and conduct of clinical trials in patients with Osteoarthritis: Recommendations from a task force of the Osteoarthritis Research Society.
        Osteoarthritis Cartilage. 1996; 4: 217-243
        • Carrabba M
        • Paresce E
        • Angelini M
        • et al.
        The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful Osteoarthritis of the knee with joint effusion.
        Eur J Rheumatol Inflamm. 1995; 15: 25-31